N@N

Biosign Offers Non-Invasive Glucose Testing at Health 2.0 Conference to Attendees

^{Published on 2011-09-26 05:05:57 - Market Wire}
 

SAN FRANCISCO, Sept. 26, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) a medical device company focused on non-invasive, cloud-based vital health monitoring, will be offering a free non-invasive glucose testing demonstration during the Health 2.0 conference being held in San Francisco today and tomorrow.

"We are providing the opportunity for anyone attending Health 2.0 to take their own readings at a special station we setup for this purpose, although the device is not yet approved by the FDA for sale in the U.S.," said Dr. Scott Jenkins, CEO of Biosign Technologies. "Allowing people to see our UFIT® medical device work for themselves is the first step to getting this breakthrough technology into the hands of patients."

UFIT® combines the power of the cloud for validation and analysis with an easy to use wrist cuff for the pain-free non-invasive measurement of vital health information. Measuring both blood glucose and blood pressure from a single device makes this application unique. Biosign offers additional data analysis through our Cloud Dx^TM platform.

Dr. Scott Jenkins, CEO of BioSign stated "Our New Cloud Dx^TM solution and non-invasive blood glucose data integrated with HealthSaaS Connected Outcomes Framework® services is a significant step forward to facilitating seamless collaboration and providing quality metrics for the healthcare ecosystem. By working together, we plan to lower the costs for payers and at the same time improve the quality of life for patients with diabetes, hypertension, and cardio-vascular diseases."

About Cloud Dx^TM

The Cloud Dx^TM brand is a trademark of Biosign Technologies Inc. and is the brand under which Biosign shall deliver services to consumers, healthcare professionals and payers. Biosign collects data from proprietary non-invasive devices, uses the cloud for validation, analysis and synthesis of the data, and then makes the information available to patients and their Circle of Care^TM. We believe Cloud Dx^TM is the future of remote healthcare monitoring and quality patient care.

About Biosign Technologies Inc

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems through its Cloud Dx^TM branded solution. Cloud Dx^TM applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose, and medication. Biosign technology combines measurement, analysis, and tools for disease and patient management to support global vital health monitoring. The UFIT® medical device delivers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation and management, and remote patient monitoring. For more information visit: [ www.biosign.com ].

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators ([ www.sedar.com ]).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.